Upcoming Medical Conferences in NetherlandsSearch Criteria : Netherlands
Amsterdam 4th International Conference on "Medical, Medicine and Health Sciences" (MMHS- 2019 Amsterdam)
May 25 - 26, 2019 | USD $500 | Amsterdam, Noord Holland
Amsterdam 4th International Conference on “Medical, Medicine and Health Sciences” (MMHS- 2019 Amsterdam) is organized by Academic Fora and will be held from May 25 - 26, 2019 at Mercure Hotel Amsterdam City, Amsterdam, North Holland, Netherlands. Main Theme: “Advances in collaborative research for Public Health, Medical and Medicine Sciences for better healthcare services to society” The conference will cover vital issues in medical, medicine and health sciences under multiple sub-themes. The aim of our conference is to support, encourage and provide a platform for networking, sharing, publishing and nurturing the potential growth of individual scholars across the globe. Conference Tracks and Sub-Themes: This conference is a premier platform for the presentation of novel and creative research results in the fields of theoretical, and applied Medical and medicine research, Health Sciences and Public Health research & practice. The conference will bring together leading researchers, social workers and scientists, students in the domain of scientific interest from around the world. The areas of interest for submission include, but are not limited to • Medical Science • Health Science • Public Health Additional details will be posted as soon as they are available.
May 26 - 29, 2019 | Maastricht, Limburg
European Atherosclerosis Society (EAS) 87th Congress is organized by European Atherosclerosis Society (EAS) and would be held during May 26 - 29, 2019 at MECC Maastricht, Maastricht, Limburg, Netherlands. Additional details will be posted as soon as they are available.
Jun 02 - 09, 2019 | EUR €850 | Amsterdam, North Holland
13th Biennial Congress of The European-African Hepato-PancreatoBiliary Association (E-AHPBA) is organized by Congress Company and will be held from Jun 02 - 05, 2019 at Beurs van Berlage, Amsterdam, North Holland, Netherlands. Description: The Netherlands is known for its evidence based research and high-quality, practice-changing nationwide randomized controlled trials in HPB surgery over the last decades. Besides this high quality research Amsterdam is known for its free way of thinking and open minded way of living. This combination gives all possibilities for an exciting E-AHPBA meeting in summer 2019 and an excellent opportunity for active interaction between HPB specialists and leading industrial partners on cutting edge technology and other innovative treatments. Additional Details will be posted as soon as they are available.
Jun 05 - 06, 2019 | Utrecht, Utrecht
Utrecht Cadaver Dissection Course is organized by Rhinoplasty Society of Europe (RSE) and will be held from Jun 05 - 06, 2019 at Utrecht, Netherlands. Additional details will be posted as soon as they are available.
Jun 11 - 13, 2019 | Amsterdam, Noord Holland
Antibody Engineering and Therapeutics Europe, Jun 11 - 13, 2019 in Amsterdam, is the #1 antibody meeting in Europe bringing together world-renowned scientists and academic researchers to deliver the latest science, technologies and partners needed to help you accelerate next generation antibodies towards commercial success. Confirmed Keynotes: • Hans Clevers, M.D., Ph.D., Group Leader, Hubrecht Institute for Developmental Biology and Stem Cell Research and Professor of Molecular Genetics, University Medical Center Utrecht and Utrecht University, The Netherlands • Jane Osbourn, Ph.D., Vice President RandD and Site Leader of MedImmune, Cambridge, United Kingdom Sessions Around 6 Key Themes: • Turning Antibody Leads into Drugs • Recent Advances in Immuno-Oncology Approaches • Bioinformatics and Repertoires in Antibody Discovery and Development • Antibody Therapeutics for Autoimmune and Neurodegenerative Diseases • Clinical Developments in Antibody Therapeutics • New Antibody Formats and Effector Functions Don't Wait! This event sold out last year and had to be moved to a new venue this year! Visit: AntibodyEngEu Time: 8:00 am - 5:00 pm Prices: Industry - Conference Only: GBP 1399.0, Academic - Conference Only: GBP 499.0 Speakers: Jane Osbourn, Ph.D. Vice President RandD and Site Leader at Medimmune, Hans Clevers, M.D., Ph.D. Group Leader and Professor of Molecular Genetics at Hubrecht Institute for Developmental Biology and Stem Cell Research and University Medical Center Utrecht and Utrecht University, Andreas Plückthun, PhD Professor and Director, Department of Biochemistry at University of Zurich Additional details will be posted as soon as they are available.
Jun 12 - 15, 2019 | CME 25.00 | EUR €850 | Utrecht, Utrecht
European Cleft Palate Craniofacial Association (ECPCA) Congress is organized by MCI Group and will be held from Jun 12 - 15, 2019 at Tivoli Vredenburg, Utrecht, Netherlands. This CME Conference has been approved for a maximum of 25 CME Credits. Conference Description: ECPCA 2019 will bring together experts, practitioners and companies involved in the treatment of cleft lip palate/craniofacial malformations. Professionals attending this congress will benefit from high-level scientific presentations, knowledge sharing and networking opportunities, with the overall goal of promoting understanding and treatment of these diseases. With the annual theme 'Future perspectives in research and therapy', we would like to explore possibilities such as robotic involvement in surgery, 3-D printing and future applications of regenerative medicine, but also include new developments in modalities eg. genetics in diagnosing craniofacial anomalies. Reasons to attend: • Interactive and practical sessions and case studies • Learn directly from your peers and tried & tested experiences • How to prepare for the advances in medicine and challenges ahead • High-quality programme with an emphasis on clinical updates and training • Shape the future of cleft palate and craniofacial surgery and treatments • Strong international focus and developments from around the world Speakers: Bannister, Patricia (United Kingdom), Berge S.J., Stefaan (Netherlands), Bonanthaya, Krishnamurthy (India), Braumann, Bert (Germany), Broeders, Ivo (Netherlands), Bulstrode, Neil (United Kingdom), Deacon, Scott (United Kingdom), DonGriot, Peter (Netherlands), Dunaway, David (United Kingdom), Evans, Kelly (United States), Fisher, David (Canada), Flores, Roberto (United States), Gordon, Chris (France), Grollemund, Bruno (France), Hens, Greet (Belgium), Hopper, Richard (United States), Kennedy, James (Netherlands), Kolby, Lars (Sweden), Koudstaal, Maarten (Netherlands), Kuo-Ting Chen, Philip (Taiwan), Maal, Thomas (Netherlands), Malda, Jos (Netherlands), Mann, Robert (United States), Mathijssen, Irene (Netherlands), Meazzini, Maria Constanza (Italy), Meshach, Ong’uti (Kenya), Mossey, Peter (United Kingdom), Persson, Martin (Sweden), Rumsey, Nichola (United Kingdom), Schachner, Peter (Austria), Semb, Gunvor (United Kingdom), Shaw, Bill (United Kingdom), Sitzman, Thomas (United Kingdom), Swan, Marc (United Kingdom), Talmant, Jean-Claude (France), Sitzman, Thomas J. (United Kingdom), van Amelsvoort, Therese (The Netherlands), Vermeesch, Joris (Belgium), Zeytinoglu Saydam, Senem (Turkey)
Jun 13 - 14, 2019 | Nijmegen, Gelderland
rTMS for depression, OCD and new developments: 2-day rTMS course is organized by neuroCare Group GmbH and will be held from Jun 13 - 14, 2019 at neuroCademy, Nijmegen, Gelderland, Netherlands. The target audience for this medical event is for clinicians, psychiatrists and psychologists who have basic knowledge of neuroscience and consider using rTMS treatment in their own practices. Also researchers wanting to use rTMS in their studies. Conference Description: The course is for academics and clinicians who want to use the technique of repetitive transcranial magnetic stimulation (rTMS) combined with psychotherapy (e.g. cognitive behavioural therapy) for the treatment of Depression, OCD and other indications as well as for researchers who want to use rTMS in research-settings. Also more advanced topics such as the use of EEG and QEEG to predict and optimize rTMS treatment, other neuromodulation techniques (tDCS, tACS) and sleep problems and chronobiology will be covered. During this course there is ample time dedicated to hands-on training with different types of rTMS equipment, supervised by one of our experienced rTMS specialists. The 2-day course will have a focus on: • The use and theoretical background of rTMS in clinical practice • The working mechanism of TMS and safety aspects • The use of rTMS in the treatment of depression • An overview of the use of rTMS in other disorders • The use of EEG and QEEG along with rTMS for safety aspects, the prediction of treatment outcome and markers for responders/non-responders. • Other neuromodulation techniques such as tDCS and tACS. Additional details will be posted as soon as they are available.
Jun 13 - 14, 2019 | Rotterdam, South Holland
3D-Culture, Organoids & Tox Screening Europe 2019 is organized by SelectBio and will be held from Jun 13 - 14, 2019 at Rotterdam Marriott Hotel, Rotterdam, South Holland, Netherlands. Course Description: SELECTBIO 3D-Culture, Organoids & Tox Screening Europe 2019 brings together researchers from around the world focusing on the emerging technologies and applications of 3D-culture and organoids, especially as they are impacting drug discovery, toxicity screening and drug development processes. Hear from and network with researchers who are currently screening for efficacy and toxicity using iPS cell lines (and cells derived thereof), and those responsible for developing the techniques and technologies in the organoids field. There will also be discussions on industry and regulatory developments that are shaping the future of 3D-culture and technologies for studying organoids in cancer research and beyond. Topics to be covered include 3D-cell based screening methods, high content screening and data management, the use of model organisms and novel approaches for phenotypic screening. Key Opinion Leaders from around the World are Participating at this Conference allowing Maximal Information Exchange and Unparalleled Networking Opportunities. Conference Topics: • 3D-Cell Culture Based Models • High-Content Screening and Imaging Technologies • iPSC-derived Cells for Toxicity Testing and Pharmaceutical Screening • Organoids • Phenotypic and High Content Screening of 3D-Model Systems • Phenotypic Drug Discovery • Screening Technologies, Instrumentation and Reagents • Stem Cells in Drug Discovery and Toxicity Screening • Technologies in 3D-Cell Culture Short Courses: Designing and Validating Assays Applied to 3D-Organoids held in conjunction with 3D-Culture, Organoids & Tox Screening Europe 2019 on 13 Jun 2019 at Rotterdam, The Netherlands. Additional details will be posted as soon as they are available.
Jun 13 - 16, 2019 | Amsterdam, Noord Holland
24th Congress of the European Hematology Association (EHA) is organized by European Hematology Association (EHA), MCI Group and will be held from Jun 13 - 16, 2019 at Amsterdam RAI Exhibition and Convention Centre, Amsterdam, Noord Holland, Netherlands. Join us at the 24th Congress of EHA Attend the premier hematology congress in Europe from June 13-16, 2019 in Amsterdam. The 24th Congress of EHA will offer you a program that includes every subspecialty in hematology, as well as networking opportunities with experts from all around the world. The EHA Congress is a forum for original data, hematological innovation and evidence-based knowledge of primary clinical relevance. The congress also provides Satellite Symposia, Updates-in-Hematology and an exhibition organized by pharmaceutical companies, national and international non-profits. The program provides a comprehensive overview of hematology while still being easy to navigate. After six years, the EHA Annual Congress is coming back to The Netherlands. We are happy to come back to RAI Amsterdam, located only six minutes by train from Schiphol Airport and fifteen minutes from Amsterdam Central Station. Congress objectives: The EHA Annual Congress is a forum for • original unpublished data, • sharing ideas about hematological innovation, as well as for • disseminating evidence-based knowledge of primary clinical relevance. Hematologists and affiliated professionals will be able to: • Enhance their knowledge of evidence-based approaches to diagnosis and treatment for hematologic diseases. • Access the latest results on clinical and translational research in hematologic disorders. • Be updated on emerging innovative techniques, diagnostic tools and risk-assessment strategies in hematology and its subspecialties. • Communicate, collaborate and network with representatives of a large international audience – medical professionals, national hematology societies, patient groups, medical industry and the media.
Jun 18 - 19, 2019 | EUR €450 | Amsterdam, North Holland
The CDDF Multi-stakeholder workshop on Involving Patients in Oncology Drug Development takes place on 18-19 June in Amsterdam, Netherlands. This workshop will look at the opportunities and challenges of incorporating the patient-relevant evidence into oncology drug development and approval process from the perspective of patients, health care providers, health authorities, HTA bodies, payers and industry and will address the following topics: • Examine the different type of patient-relevant evidence for patient-focused drug development • Exemplary models for interactions between patients’ communities, sponsors and decision-makers • Examples of qualitative and quantitative patient-experience data and its contribution to development, review, approval and access to new drugs Target Audience: The target is a multidisciplinary audience of Patient Associations, Academia Representatives, EU and US Regulatory Bodies (EMA, FDA, National Agencies), Pharmaceutical Industry, and HTAs. Programme Committee: • Academia: Axel Glasmacher (CDDF Board) • Industry representatives : Claudia Hey (Merck), Elisabeth Piault-Louis (Genentech), Marloes Van Bruggen (Roche) • Patient Advocates: Francesco De Lorenzo (ECPC, Italy) • Regulatory Authorities: Ralf Herold (EMA), Belinda King-Kallimanis (FDA) • HTA bodies: Margarida Oliveira (Infarmed), Giovanni Tafuri (EUnetHTA) Additional details will be posted as soon as they are available.